Lenalidomide
- PDF / 141,205 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 70 Downloads / 125 Views
1
Lenalidomide Reactivation of GVHD in an elderly stem cell transplant recipient?: case report A 65-year-old woman with acute myeloid leukaemia (AML) underwent allogenic stem cell transplantation. Her recovery was complicated by acute graft versus host disease (GVHD) involving her skin, which responded to topical treatment. On post-transplant day 371, her AML relapsed. At this point, she was receiving tacrolimus alone. Over the following month, she was tapered off tacrolimus, and then started on oral lenalidomide 10 mg/day. Four weeks later, a diffuse erythematous rash developed on her trunk and proximal extremities; she also reported mild diarrhoea. Topical corticosteroids were administered, with complete resolution. Author comment: "A concern with the posttransplantation administration of immunomodulatory agents such as lenalidomide is the possible reactivation or exacerbation of acute GVHD . . . Our patient’s course suggests that a mild and transient GVHD reactivation may have occurred, although we were unable to unequivocally show this." Ford CD, et al. CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT. Bone Marrow Transplantation 45: 403-404, No. 2, Feb 2010. Available from: URL: http://dx.doi.org/10.1038/bmt.2009.146 803009501 USA
0114-9954/10/1295-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Reactions 3 Apr 2010 No. 1295
Data Loading...
